APL Differentiation Syndrome (ATRA/Arsenic Trioxide Syndrome)

Overview

Differentiation syndrome (DS) is a potentially fatal inflammatory cytokine release syndrome seen during induction in acute promyelocytic leukemia (APL, t(15;17)/PML-RARA) with differentiation-inducing agents — all-trans retinoic acid (ATRA) and/or arsenic trioxide (ATO). Its former name was retinoic acid syndrome; however, since ATO alone can produce the same scenario, the term differentiation syndrome is preferred in daily practice.

The pathogenesis begins with the release of cytokines such as interleukin-1, interleukin-6, interleukin-8, and tumor necrosis factor-alpha during rapid maturation of leukemic promyelocytes under the effect of ATRA and ATO; these cytokines trigger systemic inflammatory response syndrome. Simultaneously, the expression of adhesion molecules such as CD11b, CD18, ICAM-1, and LFA-1 increases on maturing myeloid cells; this increase facilitates the adhesion of cells to the endothelium and especially their migration to the lungs.

The serine protease called cathepsin G directly causes endothelial damage and increased capillary permeability, contributing to capillary leak syndrome; as a result, microcirculatory obstruction, tissue infiltration, and fluid extravasation occur. Typically, this occurs in the first 1-3 weeks of induction (median approximately 7. day) begins; severe DS occurring early (within the first week) requires mechanical ventilation more frequently than late-onset DS and is associated with higher mortality during the induction period.

Clinically, symptoms include fever unexplained by infection, dyspnea and respiratory distress, infiltrates on chest X-ray, sudden weight gain (more than 5 kilograms), pleural or pericardial effusion, unexplained hypotension, and acute kidney injury. There is no definitive laboratory test for diagnosis; diagnosis is based on the clinical symptom cluster and exclusion of other causes, so even clinical suspicion alone is considered sufficient to start treatment.

The development of progressive hyperleukocytosis during induction, especially with the combination of ATRA and ATO, is an independent predictive finding for DS and treatment-related complications and requires close monitoring. In large cohort data, approximately one-quarter of patients treated with ATRA develop DS, and about half of these cases are moderate and half are severe in severity.

Although the reported incidence in pediatric patients varies by series, it may be higher than in adults; in some retrospective pediatric cohorts, the rate of DS during induction reached about forty percent. Early diagnosis and early initiation of dexamethasone significantly reduce mortality; delayed administration of steroids directly increases the risk of death.

The Sanz risk score, jointly developed by the GIMEMA and PETHEMA groups, stratifies patients into low, intermediate, and high-risk groups based on leukocyte and platelet counts at diagnosis; low and intermediate risk groups, with leukocyte counts below 10x10^9 cells per liter, are now collectively called standard risk, whereas patients with leukocyte counts above this threshold form the high-risk group, and differentiation syndrome is significantly more frequent in this high-risk group. The Italian-German APL0406 study demonstrated that in low- and intermediate-risk APL patients, the combination of ATRA and arsenic trioxide provided longer event-free survival and disease-free survival compared to ATRA plus anthracycline-based chemotherapy and made this chemotherapy-free approach preferred for the standard-risk group; however, it has been reported that the incidence of differentiation syndrome in regimens using both ATRA and ATO may be higher compared to regimens containing only ATRA or only ATO, so the prophylaxis threshold is kept lower in patients receiving the combination regimen.

Key considerations

• Pneumonia and other lung infections are common in neutropenic patients; even if DS is suspected, empirical antibiotic treatment should be continued until infection is ruled out.
• Sepsis and septic shock can mimic fever and hypotension seen in DS; blood cultures and lactate levels are helpful in differential diagnosis.
• Fluid overload and cardiogenic pulmonary edema can create similar dyspnea and infiltrate patterns, especially in patients receiving aggressive intravenous hydration; echocardiography and natriuretic peptide measurement can facilitate differentiation.
• Disseminated intravascular coagulation due to APL and associated alveolar or pulmonary bleeding produce respiratory findings overlapping with DS; however, low fibrinogen and thrombocytopenia highlight this condition.
• Acute respiratory distress syndrome due to other causes, such as aspiration or massive transfusion, may occur with another trigger and should be assessed independently of DS.
• Transfusion-related acute lung injury and transfusion-associated circulatory overload can cause dyspnea and infiltrates in patients recently receiving blood products and may be confused with DS.
• Pulmonary embolism can mimic DS with sudden-onset dyspnea and hypoxemia; patients with APL may also have an increased risk of thrombosis due to coagulopathy.
• Leukostasis, that is, microcirculation obstruction due to extreme leukocytosis, can occur simultaneously with DS and present overlapping findings because of elevated white blood cell counts during differentiation therapy.
• Drug-induced acute kidney injury or acute renal failure from other causes should be distinguished with drug history and urine tests, as they can mimic renal involvement of DS.
• Pericardial tamponade may arise from rapid progression of pericardial effusion during the course of DS and should be recognized as a complication separate from DS that requires urgent drainage.

Why it matters

The cornerstone of management is EARLY recognition and IMMEDIATE high-dose steroid therapy. The expert opinion article published in Blood in 2014 titled "How we prevent and treat differentiation syndrome" and the review by Montesinos and Sanz 2011 summarizing the PETHEMA group's experience define the standard treatment for DS as dexamethasone 10 mg IV twice daily (every 12 hours); this dose is continued until the findings completely resolve (usually at least 3 days) and then gradually tapered off.

Dexamethasone should be started at the first suspicion, without waiting for a definitive diagnosis; because the strongest determinant of mortality highlighted by these sources is how early the steroid is administered. Whether the differentiation agent (ATRA/ATO) should be discontinued depends on the severity of the disease: in the PETHEMA/Montesinos classification, in mild to moderate DS (three or fewer of the following findings), the agent can generally be continued without interruption; in severe DS (four or more findings) or in case of rapid progression, respiratory failure, or acute kidney injury despite dexamethasone, ATRA and/or ATO should be temporarily stopped until clinical improvement.

The PETHEMA list of findings includes: dyspnea, unexplained fever, weight gain of more than 5 kilograms, unexplained hypotension, acute kidney failure, pulmonary infiltrates on X-ray, and pleural or pericardial effusion. There is a threshold difference between guidelines regarding prophylaxis, which is clinically significant: current versions of the NCCN guideline recommend prophylaxis in patients with a white blood cell count greater than 10x10⁹/L and in all patients receiving ATRA and ATO together, regardless of white blood cell count, while the more recent PETHEMA-based expert opinion sets a lower white blood cell threshold of 5x10⁹/L for patients considered high-risk for DS.

The difference between these two thresholds represents a real divergence between guidelines in deciding which patients should start prophylactic steroids, and the threshold adopted by the institution should be clearly stated. Prednisone 0.5-1 mg/kg/day or dexamethasone is used for prophylaxis; in the PETHEMA protocol, in high-risk patients, dexamethasone 2.5 mg/m² body surface area IV every 12 hours for 15 days is recommended.

If DS develops, prophylactic steroid is immediately replaced with dexamethasone 10 mg q12h. [numeric values preserved: 9, 9] Supportive treatment includes oxygen or respiratory support, diuretics for fluid overload and effusion, strict fluid balance monitoring and daily weighing, and renal support in acute kidney injury.

In cases with progressive hyperleukocytosis that do not respond to dexamethasone, adding cytoreductive therapy such as hydroxyurea has been reported as an approach that allows continuous administration of ATRA without interruption in case series. Mortality data have changed markedly over time: in older cohorts, DS-related mortality reached up to thirty%, while in a large ATRA-anthracycline cohort from 2009, DS developed in 183 out of 739 patients (24.8%), of which 93 were severe (12.6%) and 90 were moderate (12.2%); only severe DS was associated with increased mortality.

With early recognition, prophylaxis, and widespread use of steroid protocols, DS-related mortality in current series has decreased to about 1%; this reduction provides the strongest evidence that early intervention directly alters the clinical outcome. Coagulopathy and infection accompanying APL should always be evaluated; even if fever is attributed to DS, empiric antibiotics should be considered until infection is excluded.

Critical complications

• Acute respiratory failure is the most common fatal complication of DS; it is recognized by hypoxemia and increased work of breathing, and mechanical ventilation support should be considered early.
• Acute kidney injury is recognized by rising creatinine and decreased urine output; fluid balance should be strictly maintained, and if necessary, renal replacement therapy should be planned in collaboration with nephrology.
• Pericardial tamponade occurs during DS due to sudden hemodynamic deterioration from a growing pericardial effusion; it is recognized with hypotension, jugular venous distension, and tachycardia and requires urgent pericardiocentesis.
• Disseminated intravascular coagulation and associated bleeding, particularly intracranial or pulmonary hemorrhage, are the main causes of early mortality related to APL itself; it is managed with close monitoring of fibrinogen, prothrombin time, activated partial thromboplastin time, and platelet count, along with fresh frozen plasma and platelet replacement.
• Hyperglycemia and increased infection risk related to dexamethasone are expected consequences of high-dose and prolonged steroid use; blood glucose should be monitored and unnecessary prolonged steroid use avoided.
• A re-increase in leukemic cell load and hyperleukocytosis due to the temporary discontinuation of ATRA/ATO may develop during the period when differentiation therapy is stopped; therefore, the interruption should be kept as short as possible and treatment should be resumed as soon as clinical improvement occurs.
• Leukostasis and microcirculation blockage due to progressive hyperleukocytosis can occur simultaneously with DS, worsening respiratory and neurological findings; in this case, cytoreductive therapy such as hydroxyurea can be added with the decision of hematology, but leukapheresis is not recommended due to the risk of worsening coagulopathy.
• DS recurrence is seen if dexamethasone is stopped early before the findings have fully resolved; therefore, the steroid should be tapered off and if relapse occurs, the full dose should be resumed.
• Tumor lysis syndrome can develop due to the release of potassium, phosphate, and uric acid from rapidly dying leukemic cells during induction therapy; it is recognized by hyperkalemia, hyperphosphatemia, and acute kidney injury, and is managed with hydration, uric acid-lowering therapy, and electrolyte monitoring.

Special considerations

• APL is rare during pregnancy; it is observed in approximately one case per 100,000 pregnancies. ATRA is considered relatively safe in the second and third trimesters but significantly increases the risk of fetal malformation and miscarriage in the first trimester; therefore, it is avoided during the first trimester if possible. Arsenic trioxide is considered teratogenic, genotoxic, and carcinogenic, and crosses the placenta; therefore, ATO use during pregnancy is only evaluated on a case-by-case basis in consultation with high-risk specialists, and solely to save the mother’s life. In pregnant cases developing severe DS, increasing the dexamethasone dose, temporarily interrupting ATRA and restarting at a low dose, and adding hydroxycarbamide for hyperleukocytosis have been reported; however, severe DS and concurrent coagulopathy may lead to pregnancy loss.
• The incidence of DS in pediatric patients is different from adults and varies according to series; in some retrospective cohorts, the rate of DS during induction was reported to be significantly higher than about one-fourth of the rate seen in adults. Regarding pediatric dexamethasone dosage, as there is no single verified value per kilogram agreed upon in sources, the dose should definitely be confirmed with the institutional pediatric hematology-oncology protocol.
• In geriatric patients, the risk of complications (infection, hyperglycemia, cardiac overload) due to induction chemotherapy and high-dose steroids is higher; fluid balance and steroid duration should be reviewed more frequently in this group because underlying cardiac or renal reserve may be limited.
• In a patient with chronic kidney disease, since the diagnosis of DS is based on kidney involvement, interpreting an acute rise without knowing the baseline creatinine as a sign of DS can be misleading; comparison with the baseline value is essential.
• In a patient with liver failure, ATRA metabolism and the risk of coagulopathy may change, so monitoring of transaminases and bilirubin should be intensified, and the dosage of the differentiation agent should be reviewed with hematology in terms of hepatotoxicity.
• In immunosuppressed or neutropenic patients, differentiating fever due to DS from fever due to infection is particularly difficult; empirical broad-spectrum antibiotics should be started in this group without delaying DS treatment, and both should be managed simultaneously.

Follow-up plan

After starting dexamethasone, clinical response (fever, oxygenation, weight and fluid balance, creatinine, effusion size) should be closely monitored within 24-48 hours; if there is no improvement or the condition worsens, the patient should be reassessed as having severe DS and coordination should be ensured between the intensive care and hematology teams while stopping ATRA/ATO. Dexamethasone should be continued until the findings fully resolve (usually at least 3 days), and then the dose should be gradually reduced and discontinued; early discontinuation may result in recurrence of DS.

If ATRA or ATO has been stopped, treatment can be restarted after the clinical condition fully recovers with the decision of hematology. For simultaneous monitoring of coagulopathy, fibrinogen, prothrombin time, activated partial thromboplastin time, platelet count, and D-dimer should be measured at regular intervals; it should be kept in mind that bleeding is the main cause of early deaths due to APL.

In patients showing progressive leukocytosis, the white blood cell trend should be monitored daily, and rapid increases should be considered as a predictor increasing the risk of DS and treatment-related complications. All APL and DS management should be continued under hematology-oncology supervision; this protocol is prepared solely to accelerate the initial bedside recognition and the initiation of steroids.

Discharge is planned only after DS findings have fully resolved, with hematology approval, and within the scope of the APL induction protocol; the patient experiencing DS should be clearly instructed to seek immediate care in case of recurrent fever, shortness of breath, or sudden weight gain. Diagnostic and dose thresholds should be confirmed with institutional and up-to-date guidelines; the pediatric dexamethasone dose should be consulted with the institutional pediatric hematology protocol with the note CONFIRM.